

Dr. Sven Ruf



Dr. Sven Ruf completed his PhD studies in synthetic organic chemistry with Prof. Regitz at the University of Kaiserslautern in 1999. Afterwards he spent the year 2000 with postdoctoral studies in the group of Prof. Trost at Stanford University. In 2001 he joined the medicinal chemistry department of the Sanofi-Aventis Deutschland GmbH and currently holds the position of a senior scientist. He has been responsible for the lead discovery strategies deployed in several early research projects and became the chemistry leader of the Cathepsin A project. Among his other research interests are phenotypic screening approaches and the impact of macrocycles on drug discovery.

Selected publications on Cathepsin A:

Ruf, Sven et. al., **Novel β -amino acid derivatives as Inhibitors of Cathepsin A**, *J. Med. Chem.*, **2012**, 7636-7649

Ruf, Sven et. al., **Inhibition of CatA: an emerging strategy for the treatment of heart failure**, *Future Med. Chem.*, **2013**, 399-409

Schreuder, Herman A. et. al., **Crystal structure of cathepsin A, a novel target for the treatment of cardiovascular diseases**, *Biochem. Biophys. Res. Commun.*, **2014**, 451-456